Literature DB >> 24454599

[Not Available].

Abdelmounaim Qarro1, Mohammed Asseban1, Khalil Bazine1, Mohammed Najoui1, Jamaleddine Samir1, Youssef Ouhbi1, Amoqrane Beddouch1, Mohammed Lezrek1, Mohammed Alami1.   

Abstract

Year:  2014        PMID： 24454599      PMCID： PMC3896557          DOI： 10.5489/cuaj.1450

Source DB:  PubMed          Journal:  Can Urol Assoc J        ISSN： 1911-6470            Impact factor:   1.862


× No keyword cloud information.
  58 in total

1.  Detrol LA and Diropan XL for overactive bladder.

Authors: 
Journal:  Med Lett Drugs Ther       Date:  2001-04-02       Impact factor: 1.909

Review 2.  The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society.

Authors:  Paul Abrams; Linda Cardozo; Magnus Fall; Derek Griffiths; Peter Rosier; Ulf Ulmsten; Philip Van Kerrebroeck; Arne Victor; Alan Wein
Journal:  Urology       Date:  2003-01       Impact factor: 2.649

Review 3.  International Union of Pharmacology. XVII. Classification of muscarinic acetylcholine receptors.

Authors:  M P Caulfield; N J Birdsall
Journal:  Pharmacol Rev       Date:  1998-06       Impact factor: 25.468

Review 4.  Tolterodine use for symptoms of overactive bladder.

Authors:  J M Ruscin; N E Morgenstern
Journal:  Ann Pharmacother       Date:  1999-10       Impact factor: 3.154

5.  Pharmacokinetics, efficacy, and safety of intravesical formulation of oxybutynin in patients with detrusor overactivity.

Authors:  Kari Lehtoranta; Hanna Tainio; Eeva Lukkari-Lax; Tiina Hakonen; Teuvo L J Tammela
Journal:  Scand J Urol Nephrol       Date:  2002-02

6.  Effects of potassium channel modulators on myogenic spontaneous phasic contractile activity in human detrusor from neurogenic patients.

Authors:  Stephanie Oger; Delphine Behr-Roussel; Diane Gorny; Jacques Bernabé; Eva Comperat; Emmanuel Chartier-Kastler; Pierre Denys; Francois Giuliano
Journal:  BJU Int       Date:  2010-12-16       Impact factor: 5.588

7.  Measurement of oxybutynin and its N-desethyl metabolite in plasma, and its application to pharmacokinetic studies in young, elderly and frail elderly volunteers.

Authors:  K M Hughes; J C Lang; R Lazare; D Gordon; S L Stanton; J Malone-Lee; M Geraint
Journal:  Xenobiotica       Date:  1992-07       Impact factor: 1.908

8.  Efficacy and safety of repeated dosing of netupitant, a neurokinin-1 receptor antagonist, in treating overactive bladder.

Authors:  F Haab; B Braticevici; G Krivoborodov; M Palmas; M Zufferli Russo; C Pietra
Journal:  Neurourol Urodyn       Date:  2013-06-14       Impact factor: 2.696

9.  Multicenter phase III trial studying trospium chloride in patients with overactive bladder.

Authors:  Delbert Rudy; Kevin Cline; Richard Harris; Kenneth Goldberg; Roger Dmochowski
Journal:  Urology       Date:  2006-02       Impact factor: 2.649

10.  Dicyclomine, benzhexol and oxybutynine distinguish between subclasses of muscarinic binding sites.

Authors:  L Nilvebrant; B Sparf
Journal:  Eur J Pharmacol       Date:  1986-04-09       Impact factor: 4.432
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.